Celerion Adds Containment Room
Modular containment room at Belfast facility allows studies of biologics and vaccines.
Celerion added a containment room at the Belfast, Northern Ireland, UK facility, the company announced in a press release. The new containment room will allow Celerion to develop programs that require studies utilizing biologics, as well as vaccines with primary and secondary containment.
The modular facility uses a negative-pressure processing room that houses a Biosafety Level (BSL-2) cabinet. The room enables processing of live class 2 and class 3 biological products.
Celerion’s facility in Belfast also has extensive early-stage clinical capabilities based on First-In-Human experience with both NCEs and biologics, as well as bioequivalence, biosimilars, obesity, ophthalmic, and gastro-intestinal studies.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
